Nautilus Biotechnology Stock Investor Sentiment

NAUT Stock  USD 2.30  0.06  2.68%   
Slightly above 58% of all Nautilus Biotechnology's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that some traders are interested. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
  

Nautilus Biotechnology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
few days ago at www.macroaxis.com         
Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
Macroaxis News
over two weeks ago at finance.yahoo.com         
3 US Penny Stocks With Market Caps Up To 400M
Yahoo News
over three weeks ago at globenewswire.com         
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy...
Macroaxis News: globenewswire.com
over three weeks ago at insidermonkey.com         
Nautilus Biotechnology, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
Nautilus Biotechnology Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Nautilus Biotechnology GAAP EPS of -0.13 beats by 0.04
seekingalpha News
over a month ago at www.macroaxis.com         
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Nautilus Marine Services Trading Up 5.9 percent Whats Next?
news
over a month ago at news.google.com         
We Think Nautilus Biotechnology Can Afford To Drive Business Growth - Yahoo Finance
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
Yahoo News
over two months ago at news.google.com         
Nautilus Biotechnology senior VP sells over 134k in company stock - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 47031 shares by Mary Godwin of Nautilus Biotechnology at 2.865 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Sujal Patel of 41654 shares of Nautilus Biotechnology at 2.9204 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.

Nautilus Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
09/16/2024
2
Disposition of 35000 shares by Mary Godwin of Nautilus Biotechnology at 2.8534 subject to Rule 16b-3
09/17/2024
3
Acquisition by Sujal Patel of 41654 shares of Nautilus Biotechnology at 2.9204 subject to Rule 16b-3
09/18/2024
4
Disposition of 47031 shares by Mary Godwin of Nautilus Biotechnology at 2.865 subject to Rule 16b-3
09/23/2024
5
Nautilus Biotechnology senior VP sells over 134k in company stock - Investing.com
09/25/2024
6
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
10/25/2024
7
Nautilus Biotechnology Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
10/30/2024
8
3 US Penny Stocks With Market Caps Up To 400M
11/07/2024
9
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
11/08/2024
10
Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3
11/22/2024

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.